A randomized, parallel arm, placebo-controlled, double-blind, multiple-dose study of the safety and efficacy of RN624 in adults with moderate-to-severe pain due to osteoarthritis of the knee

Trial Profile

A randomized, parallel arm, placebo-controlled, double-blind, multiple-dose study of the safety and efficacy of RN624 in adults with moderate-to-severe pain due to osteoarthritis of the knee

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2010

At a glance

  • Drugs Tanezumab (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer; Rinat Neuroscience
  • Most Recent Events

    • 14 Oct 2010 Results have been reported in The Lancet.
    • 14 Jun 2008 Primary endpoint achieved; results reported at EULAR 2008.
    • 04 Jan 2008 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top